Press Release

Chinese Life Sciences Company Lepu Medical Technology Lists Its GDRs on SIX Swiss Exchange

21 September, 2022

Today, Lepu Medical Technology (Ticker "LEPU") becomes the fifth company to list Global Depository Receipts (GDRs) on SIX Swiss Exchange since the launch of “China-Switzerland Stock Connect” in July this year.

Lepu Medical Technology has placed 17,684,396 GDRs at an offer price of USD 12.68 per GDR, with one GDR representing an interest in five A shares of the company. The company has raised gross proceeds of approximately USD 224 million from the offering.

Beijing-based Lepu Medical Technology was established in 1999 and went public in 2009 on Shenzhen Stock Exchange. The company is specialized in the development, manufacture and marketing of high-tech medical devices and equipment. Its products are used in the fields of cardiovascular interventions, structural heart diseases, cardiac rhythm management, anesthesia and critical care, in vitro diagnostics and general surgery and are sold in more than 80 countries worldwide.

Dr. PU Zhongjie, Chairman of the Board and Head of Technology of Lepu Medical Technology says: “We are delighted to complete our GDR offering and listing on SIX Swiss Exchange today. This is the start of a new and exciting chapter for us at Lepu Medical. We look forward to connecting more deeply with global investors and partners, and bringing our innovative cardiovascular disease management solutions to more parts of the world.”

Jos Dijsselhof, CEO SIX, emphasizes: “We are delighted to welcome Lepu Medical Technology to our exchange today. We see a high interest for GDR-listings from Chinese companies – so far especially from the sectors renewable energy and life sciences. This is a great proof of the attractiveness of SIX Swiss Exchange for internationally active, growth-seeking companies. I am convinced that with today's listing of its GDRs, Lepu Medical Technology is taking a decisive step towards its worldwide expansion as well as further raising its profile globally.”

More information about the company is available here.

Copyright® BME 2024
[ ]